Merck KGaA taps Cyclica for AI-based screening of protein-drug interactions  FierceBiotech

Merck KGaA has licensed a cloud-based artificial intelligence proteome screening platform from the Toronto-based Cyclica.



Source link

READ  Artificial Intelligence Is Powerful—And Misunderstood. Here's How We Can Protect Workers - TIME

LEAVE A REPLY

Please enter your comment!
Please enter your name here